All News Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Real-time Estimate Cboe BZX Other stock markets 09:29:56 27/06/2024 pm IST			5-day change	1st Jan Change
2.535 ^USD	-12.28%		-9.09%	-8.11%

29/05	Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	CI
14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape	04:10pm	AQ
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides	29/05	AQ
Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29/05	CI
Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14/05	AQ
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05	AQ
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05	AQ
Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	28/03	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	28/03	MT
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024	27/03
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03	AQ
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03	AQ
Cellectar Biosciences : Corporate Presentation - March 2024	18/03	PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03	AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03	AQ
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03	CI
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02	AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

All News

Filters